Mavoglurant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mavoglurant
Mavoglurant.svg
Names
IUPAC name
Methyl (3aR,4S,7aR)-4-hydroxy-4-[(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate
Other names
AFQ056
Identifiers
543906-09-8 YesY
3D model (Jmol) Interactive image
ChemSpider 8102466
ECHA InfoCard 100.219.728
7586
PubChem 9926832
UNII GT0I9SV4F6
Properties
C19H23NO3
Molar mass 313.40 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.[1] It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).[2]

Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials.[1][3] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome have been discontinued by the end of 2014.[4] Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.[5]
Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.[6][7]
In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.[8]
Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder.[9]

Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.[10]

See also[edit]

References[edit]

  1. ^ a b P. Cole (2012). "Mavoglurant". Drugs of the Future. 37 (1): 7–12. doi:10.1358/dof.2012.37.1.1772147 (inactive 2017-01-15). 
  2. ^ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA; et al. (2011). "AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome". Neurobiology of disease. 42 (3): 311–7. doi:10.1016/j.nbd.2011.01.022. PMID 21316452. 
  3. ^ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K.; et al. (2011). "Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056". Science Translational Medicine. 3 (64): 64ra1. doi:10.1126/scitranslmed.3001708. PMID 21209411. 
  4. ^ http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/
  5. ^ "AFQ056 drug improves symptoms in Fragile X patients: Study". news-medical.net. January 9, 2011. 
  6. ^ Kumar, R; Hauser, R. A.; Mostillo, J; Dronamraju, N; Graf, A; Merschhemke, M; Kenney, C (Sep 2013). "Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients". Int J Neurosci. 126 (1): 20–4. doi:10.3109/00207454.2013.841685. PMID 24007304. 
  7. ^ "NHI Clinical trials". 
  8. ^ "Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking". 
  9. ^ "Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD)". 
  10. ^ FRAXA (2014). "Novartis Discontinues Development of mavoglurant (AFQ056) for Fragile X Syndrome". 


Retrieved from "https://en.wikipedia.org/w/index.php?title=Mavoglurant&oldid=760245426"